BiotechTube

BIIB074 + Placebo

Phase 3Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Trigeminal Neuralgia

Conditions

Trigeminal Neuralgia

Trial Timeline

Mar 1, 2023 → Sep 29, 2026

NCT ID
NCT03637387

About BIIB074 + Placebo

BIIB074 + Placebo is a phase 3 stage product being developed by Biogen for Trigeminal Neuralgia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03637387. Target conditions include Trigeminal Neuralgia.

What happened to similar drugs?

1 of 2 similar drugs in Trigeminal Neuralgia were approved

Approved (1) Terminated (1) Active (0)
✅GalcanezumabEli LillyApproved
❌BIIB074 + PlaceboBiogenPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT03070132Phase 3Withdrawn
NCT03637387Phase 3Withdrawn
NCT03339336Phase 2Terminated
NCT02935608Phase 2Completed
NCT02917187Phase 2Completed
NCT02831517Phase 1Completed

Competing Products

7 competing products in Trigeminal Neuralgia

See all competitors
ProductCompanyStageHype Score
GalcanezumabEli LillyApproved
43
Erenumab-AooeAmgenPhase 2
27
Rimegepant + PlaceboPfizerPhase 2
27
BIIB074 Treatment A + BIIB074 Treatment B + BIIB074 Treatment C + BIIB074 Treatment DBiogenPhase 1
26
CNV1014802 + PlaceboBiogenPhase 1
26
CNV1014802 + PlaceboBiogenPhase 2
32
BIIB074 + PlaceboBiogenPhase 3
29